International Scholarly Research Notices / 2011 / Article / Tab 1 / Review Article
Novel Pharmacological Interventions to Maintain Sinus Rhythm after DC Cardioversion Study Study design N Followup (months) ACE/ARB Comparator drug Main findings Van den Berg et al. [59 ] Randomised, double blind 18 1.5 Lisinopril Placebo Maintenance of SR: 71% with lisinopril versus 36% with placebo Madrid et al. [28 ] Randomised, open label 154 2 Irbesartan No irbesartan Reduction in the risk of AF recurrence with irbesartan: adjusted HR (95% CI): 0.19 (0.04–0.86);
𝑃
=
0
.
0
3
Ueng et al. [29 ] Randomised, open label 145 9 Enalapril No enalapril Recurrence of AF: 4.3% with enalapril versus 14.7% without,
𝑃
=
0
.
0
6
7
. Probability of remaining in SR at 4 weeks: 84.3 versus 61.3%,
𝑃
=
0
.
0
0
2
.
𝑃
=
0
.
0
4
1
Madrid et al. [27 ] Randomised, open label 60 7.3 Irbesartan No irbesartan Patients remaining free of AF at 1 yr: irbesartan 300 mg + amiodarone = 77%, irbesartan 150 mg + amiodarone = 65%, amiodarone alone = 52% (
𝑃
=
0
.
0
0
1
versus irbesartan 300 mg + amiodarone) Grecu et al. [56 ] Randomised, open label 36 12 Perindopril Placebo Maintenance of SR: 37% with perindopril versus 20% with placebo. Time interval to recurrences was significantly higher in ACEI-treated patients (7.06 ± 1.02 versus 4.50 ± 0.93 months;
𝑃
=
0
.
0
3
4
) Tveit et al. [57 ] (CAPRAF study) Randomised, double blind 137 6 Candesartan Placebo Recurrence of AF: 71% with candesartan versus 65% with placebo
𝑃
=
n
s
Belluzzi et al. [60 ] Randomised, double blind 62 36 Ramipril Placebo Recurrence of AF: 10% with ramipril versus 32% with placebo (
𝑃
<
0
.
0
3
, Kaplan-Meier, log-rank test) Disertori et al. [58 ] (GISSI-AF) Randomised, double blind 1,442 12 Valsartan Placebo Recurrence of AF: 51.4% with valsartan versus 52.1% with placebo.
𝑃
=
0
.
7
3
